Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a novel combination of non-toxic dietary and hyperbaric oxygen therapies.

11 Jun 2015

ASU, Banner Health form new research alliance to advance treatment for neurodegenerative diseases

Arizona State University and Banner Health today announced a new research alliance to advance the scientific study, treatment and prevention of Alzheimer's, Parkinson's and other neurodegenerative diseases.

11 Jun 2015

Research progress with promising Alzheimer's drug Xanamem

Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders, is pleased to announce that it has received ethics approval to initiate the third and final stage of the second Phase I trial of its lead Alzheimer’s drug candidate, Xanamem™.

11 Jun 2015

CMU scientists identify how specific concrete objects are coded in the brain

Thanks to Carnegie Mellon University advances in brain imaging technology, we now know how specific concrete objects are coded in the brain, to the point where we can identify which object, such as a house or a banana, someone is thinking about from its brain activation signature.

10 Jun 2015

FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

Amyloid precursor protein (APP), a key protein implicated in the development Alzheimer's disease, may play an important role in eye and muscle health. In a new report published in the June 2015 issue of The FASEB Journal, scientists have discovered that when proteins that bind to the APP, called FE65 and FE65L1, are deleted, they cause cataracts and muscle weakness in mice.

10 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

New UAB research identifies link between temporal lobe epilepsy and memory loss

New research from the University of Alabama at Birmingham identifies an epigenetic cause for why patients with temporal lobe epilepsy tend to have memory loss, and suggests a potential way to reverse that loss.

8 Jun 2015

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

8 Jun 2015

Dementia Friends Canada launched to support Canadians living with dementia

The Honourable Rona Ambrose, Minister of Health, along with Mimi Lowi-Young, CEO of the Alzheimer Society of Canada, officially launched Dementia Friends Canada to support the growing number of Canadians living with dementia.

7 Jun 2015

Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Armed with new knowledge about how neurodegenerative diseases alter brain structures, increasing numbers of neurologists, psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients. These imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.

5 Jun 2015

Finding could help researchers develop new methods to prevent cognitive decline in Alzheimer's disease

The process that allows our brains to learn and generate new memories also leads to degeneration as we age, according to a new study by researchers at MIT.

5 Jun 2015

Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Scientists at Duke Medicine have produced a 3-D map of the human brain stem at an unprecedented level of detail using MRI technology.

4 Jun 2015

Scientists identify gene mutation that causes color blindness

A rare eye disorder marked by color blindness, light sensitivity, and other vision problems can result from a newly discovered gene mutation identified by an international research team, including scientists from Columbia University Medical Center.

3 Jun 2015

New UA research reveals factors that can impact aging adults' quality of life

As the world's population of older adults increases, so do conversations around successful aging -- including seniors' physical, mental and social well-being.

2 Jun 2015

Key lifestyle changes could help reduce risk of cognitive decline

The evidence is mounting: People can reduce their risk of cognitive decline by making key lifestyle changes. That is the conclusion of a new research summary published online today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

1 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

The rapidly emerging field of precision medicine is a "disruptive innovation" that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week's issue of the New England Journal of Medicine.

1 Jun 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

30 May 2015

Iron may underlie effect of Alzheimer’s risk allele

Ferritin in the cerebrospinal fluid of patients with Alzheimer’s disease is associated with the APOE ε4 risk allele and predicts cognitive outcomes, a study shows.

29 May 2015

Alzheimer's Disease News and Research

Further Reading

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

ASU, Banner Health form new research alliance to advance treatment for neurodegenerative diseases

Research progress with promising Alzheimer's drug Xanamem

CMU scientists identify how specific concrete objects are coded in the brain

FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

New UAB research identifies link between temporal lobe epilepsy and memory loss

GBD analysis shows over 95% of global population has health problems

Dementia Friends Canada launched to support Canadians living with dementia

Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Finding could help researchers develop new methods to prevent cognitive decline in Alzheimer's disease

Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Scientists identify gene mutation that causes color blindness

New UA research reveals factors that can impact aging adults' quality of life

Key lifestyle changes could help reduce risk of cognitive decline

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Iron may underlie effect of Alzheimer’s risk allele

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News